New research offers fresh hope to patients with colorectal cancer, as advances in liquid biomarker technologies are poised to reshape detection, diagnosis and treatment of the disease.

Colorectal cancer (CRC) remains one of the most heterogeneous malignancies, with substantial variability in molecular characteristics, therapeutic response, and clinical outcomes. Among the four consensus molecular subtypes (CMS1–CMS4), each defined by distinct biological and clinical features, CMS4—the mesenchymal subtype—is characterized by the most aggressive disease progression, extensive stromal infiltration, and a markedly poor prognosis. Despite advances in transcriptomic profiling, the clinical implementation of CMS classification remains limited due to the lack of robust and clinically accessible biomarkers capable of accurately distinguishing these subtypes. 

hijacks the gene regulatory blueprint of normal vascular differentiation to drive tumor angiogenesis —without evolving an entirely new mechanism.

single-cell multi-omics and a 3D gene regulatory map built from an hESC-based vascular differentiation system, the team pinpointed the late progenitor stage as the developmental origin of tumor endothelial cell identity.

receptor (ITGAV) was identified as a key mediator and validated as a therapeutic target: its inhibition suppressed tumor vascularization and growth in a colorectal cancer model.